These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 34674615)

  • 21. Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease.
    Rizzari C; Cazzaniga G; Coliva T; De Angelis C; Conter V
    Expert Rev Anticancer Ther; 2011 Sep; 11(9):1391-401. PubMed ID: 21929313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of combined WT1 and multiparameter flow cytometry assessment for measurable residual disease after induction in non-APL acute myeloid leukemia.
    Ding Y; Liu Z; Wang H; Xiong S; Zhai Z
    Scand J Clin Lab Invest; 2023 Sep; 83(5):340-347. PubMed ID: 37355341
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia.
    Aitken MJL; Ravandi F; Patel KP; Short NJ
    J Hematol Oncol; 2021 Sep; 14(1):137. PubMed ID: 34479626
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Minimal residual disease in acute myelogenous leukemia.
    Cruz NM; Mencia-Trinchant N; Hassane DC; Guzman ML
    Int J Lab Hematol; 2017 May; 39 Suppl 1(Suppl 1):53-60. PubMed ID: 28447422
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.
    Mulé MP; Mannis GN; Wood BL; Radich JP; Hwang J; Ramos NR; Andreadis C; Damon L; Logan AC; Martin TG; Hourigan CS
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):1974-1982. PubMed ID: 27544285
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia.
    Onecha E; Linares M; Rapado I; Ruiz-Heredia Y; Martinez-Sanchez P; Cedena T; Pratcorona M; Oteyza JP; Herrera P; Barragan E; Montesinos P; Vela JAG; Magro E; Anguita E; Figuera A; Riaza R; Martinez-Barranco P; Sanchez-Vega B; Nomdedeu J; Gallardo M; Martinez-Lopez J; Ayala R
    Haematologica; 2019 Feb; 104(2):288-296. PubMed ID: 30093399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia.
    Zhang R; Yang JY; Sun HQ; Jia H; Liao J; Shi YJ; Li G
    Eur Rev Med Pharmacol Sci; 2015; 19(14):2679-88. PubMed ID: 26221900
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monitoring of minimal residual disease in acute myeloid leukemia.
    Kern W; Haferlach C; Haferlach T; Schnittger S
    Cancer; 2008 Jan; 112(1):4-16. PubMed ID: 18000811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of a Next-generation Sequencing-based Gene Panel Test to Detect Measurable Residual Disease in Acute Myeloid Leukemia.
    Kim JJ; Jang JE; Lee HA; Park MR; Kook HW; Lee ST; Choi JR; Min YH; Shin S; Cheong JW
    Ann Lab Med; 2023 Jul; 43(4):328-336. PubMed ID: 36843401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial.
    Yin JA; O'Brien MA; Hills RK; Daly SB; Wheatley K; Burnett AK
    Blood; 2012 Oct; 120(14):2826-35. PubMed ID: 22875911
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.
    Debarri H; Lebon D; Roumier C; Cheok M; Marceau-Renaut A; Nibourel O; Geffroy S; Helevaut N; Rousselot P; Gruson B; Gardin C; Chretien ML; Sebda S; Figeac M; Berthon C; Quesnel B; Boissel N; Castaigne S; Dombret H; Renneville A; Preudhomme C
    Oncotarget; 2015 Dec; 6(39):42345-53. PubMed ID: 26486081
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimal Measurable Residual Disease Testing for Acute Myeloid Leukemia.
    Xiao W; Petrova-Drus K; Roshal M
    Surg Pathol Clin; 2019 Sep; 12(3):671-686. PubMed ID: 31352980
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Accurate and Sensitive Analysis of Minimal Residual Disease in Acute Myeloid Leukemia Using Deep Sequencing of Single Nucleotide Variations.
    Delsing Malmberg E; Rehammar A; Pereira MB; Abrahamsson J; Samuelsson T; Ståhlman S; Asp J; Tierens A; Palmqvist L; Kristiansson E; Fogelstrand L
    J Mol Diagn; 2019 Jan; 21(1):149-162. PubMed ID: 30273780
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel Tools for Diagnosis and Monitoring of AML.
    Guijarro F; Garrote M; Villamor N; Colomer D; Esteve J; López-Guerra M
    Curr Oncol; 2023 May; 30(6):5201-5213. PubMed ID: 37366878
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The minimal that kills: Why defining and targeting measurable residual disease is the "Sine Qua Non" for further progress in management of acute myeloid leukemia.
    Bewersdorf JP; Shallis RM; Boddu PC; Wood B; Radich J; Halene S; Zeidan AM
    Blood Rev; 2020 Sep; 43():100650. PubMed ID: 31883804
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular Minimal Residual Disease Testing in Acute Myeloid Leukemia: A Review for the Practicing Clinician.
    Hantel A; Stock W; Kosuri S
    Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):636-647. PubMed ID: 30006258
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A mind map for managing minimal residual disease in acute myeloid leukemia.
    Benton CB; Ravandi F
    Clin Adv Hematol Oncol; 2017 Nov; 15(11):859-867. PubMed ID: 29200419
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Test Then Erase? Current Status and Future Opportunities for Measurable Residual Disease Testing in Acute Myeloid Leukemia.
    Blackmon AL; Hourigan CS
    Acta Haematol; 2024; 147(2):133-146. PubMed ID: 38035547
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of flow cytometry and next-generation sequencing in minimal residual disease monitoring of acute myeloid leukemia: One institute's practical clinical experience.
    F McGowan P; D Hyter S; Cui W; Plummer RM; Godwin AK; Zhang D
    Int J Lab Hematol; 2022 Feb; 44(1):118-126. PubMed ID: 34585519
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing.
    Salipante SJ; Fromm JR; Shendure J; Wood BL; Wu D
    Mod Pathol; 2014 Nov; 27(11):1438-46. PubMed ID: 24743218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.